Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis

Oncology

Volumn 80, Issue 1-2, 2011, Pages 63-69

  Nagano, Hiroaki ^a   Wada, Hiroshi ^a   Kobayashi, Shogo ^a   Marubashi, Shigeru ^a   Eguchi, Hidetoshi ^a   Tanemura, Masahiro ^a   Tomimaru, Yoshito ^a   Osuga, Keigo ^a   Umeshita, Koji ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Arterial infusion chemotherapy; Hepatocellular carcinoma; Interferon; Portal vein tumor thrombosis

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; DECARBOXYPROTHROMBIN; FLUOROURACIL; OIF; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHILL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG FEVER; DRUG RESPONSE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN MANIFESTATION; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR THROMBUS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 79958061940     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328281     Document Type: Article

References (52)

1. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 5. Tokyo, Liver Cancer Study Group of Japan, 2008.
2. Yamakado K, Tanaka N, Nakatsuka A, et al: Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol 1999; 30: 660-668. (Pubitemid 29151908)
3. The Cancer of the Liver Italian Program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755.
4. Asahara T, Itamoto T, Katayama K, et al: Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology 1999; 46: 1862-1869. (Pubitemid 29366361)
5. Tanaka A, Morimoto T, Yamaoka Y: Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996; 43: 637-643. (Pubitemid 26190123)
6. Furuse J, Iwasaki M, Yoshino M, et al: Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997; 204: 787-790. (Pubitemid 27369042)
7. Lee HS, Kim JS, Choi IJ, et al: The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997; 79: 2087-2094. (Pubitemid 27227372)
8. Ando E, Yamashita F, Tanaka M, et al: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-1896. (Pubitemid 27200371)
9. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H: Hepatic arterial infusion chemotherapy using low-dose 5-fuluorouracil and cisplatin for asvanced hepatocellular carcinoma. Oncology 2010; 78: 148-153.
10. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681. (Pubitemid 29334445)
11. Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-1991.
12. Kaneko S, Urabe T, Kobayashi K: Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62: 69-73. (Pubitemid 34702023)
13. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21: 421-427. (Pubitemid 46606469)
14. Enjoji M, Morizono S, Kotoh K, Kohjima M, Miyagi Y, Yoshimoto T, Nakamura M: Reevaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5685-5687. (Pubitemid 41684924)
15. Obi S, Yoshida H, Toune R, et al: Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997. (Pubitemid 43673215)
16. Llovet JM, Sala M, Castells L, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-58. (Pubitemid 30033689)
17. Miyamoto A, Umeshita K, Sakon M, et al: Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy with-interferon and oral tegaful/uracil. J Gastroenterol Hepatol 2000; 15: 1447-1451. (Pubitemid 32052922)
18. Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442. (Pubitemid 34081374)
19. Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 57-64.
20. Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M: Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. J Gastroenterol 2007; 42: 501-506. (Pubitemid 47050015)
21. Nagano H, Sakon M, Eguchi H, et al: Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2007; 54: 172-179. (Pubitemid 46511670)
22. Nagano H, Miyamoto A, Wada H, et al: Interferon-and 5-fluorouracil combination therapy following palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk and multiple nodules. Cancer. 2007; 110: 2493-2501. (Pubitemid 350174935)
23. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655. (Pubitemid 13149996)
24. Toyoda H, Nakano S, Kumada T, et al: The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52: 295-299.
25. Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, et al: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intraarterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int. 2007; 27: 1209-1216. (Pubitemid 47543149)
26. Poon RT, Fan ST, Ng IO, et al: Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003; 237: 376-383. (Pubitemid 38176453)
27. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, Yokoyama Y, Takami T, Omori K, Kawaguchi K, Tsuchiya M, Terai S, Sakaida I, Okita K: Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005; 40: 70-78. (Pubitemid 40796335)
28. Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K: Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol. 2007; 13: 280-284. (Pubitemid 46231333)
29. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
30. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-320.
31. Brinkmann V, Geiger T, Alkan S, et al: Interferon alpha increases the frequency of interferon gamma-producing human CD4+T cells. J Exp Med 1993; 178: 1655-1663. (Pubitemid 23318444)
32. Sangfelt O, Erickson S, Castro J, et al: Molecular mechanisms underlying interferonalpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18: 2798-810. (Pubitemid 29250869)
33. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473-3486. (Pubitemid 20194083)
34. Damdinsuren B, Nagano H, Sakon M, et al: Interferon-is more potent than interferon-in human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003; 10: 1184-1190. (Pubitemid 40486814)
35. Eguchi H, Nagano H, Yamamoto H, et al: Augmentation of anti-tumor activity of 5-FU by IFN-is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881-2890. (Pubitemid 30482131)
36. Kondo M, Nagano H, Wada H, et al: Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-/receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 1277-1286. (Pubitemid 40175781)
37. Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M: Combination of interferon-and 5-fluorouracil inhibits endothelial cell growth through regulation of angiogenic factors released by tumor cells. BMC Cancer 2009; 9: 361-372.
38. Yamamoto T, Nagano H, Sakon M, et al: Partial contribution of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7884-7895. (Pubitemid 39587527)
39. Nakamura M, Nagano H, Sakon M, et al: Role of Fas/FasL pathway in combination therapy with interferon-and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007; 46: 77-88. (Pubitemid 44827417)
40. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T: Integration of interferon-/signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523. (Pubitemid 36975769)
41. Hagiwara S, Kudo M, Nakatani T, Sakaguchi Y, Nagashima M, Fukuta N, Kimura M, Hayakawa S, Munakata H: Combination therapy with PEG-IFN-and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. Br J Cancer 2007; 97: 1532-1537. (Pubitemid 350175847)
42. Yano H, Iemura A, Haramaki M, et al: Interferonreceptor expression and growth inhibition by interferon in human liver cancer cell lines. Hepatology 1999; 29: 1708-1717. (Pubitemid 29247043)
43. Damdinsuren B, Nagano H, Wada H, et al: Interferon-receptors are important for antiproliferative effect of interferon-against human hepatocellular carcinoma cells. Hepatol Res 2007; 37: 77-83. (Pubitemid 46403843)
44. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M: Activation of Wnt/-catenin signalling pathway induces chemoresistance to interferon-/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100: 1647-1658.
45. Tomimaru Y, Eguchi H, Wada H, Noda H, Murakami M, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H: Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 2010; 102: 1483-1490.
46. Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H: The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol (in press).
47. Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, Wada H, Noda T, Dono K, Umeshita K, Monden M: A pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112: 1765-1771. (Pubitemid 351536836)
48. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
49. Yang ZF, Poon RT, Liu Y, Lau CK, Ho DW, Tam KH, Lam CT, Fan ST: High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. Mol Cancer Ther 2006; 5: 2261-2270. (Pubitemid 44530463)
50. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
51. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
52. Murakami M, Kobayashi S, Marubashi S, Tomimaru Y, Noda T, Wada H, Eguchi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H: Tyrosine kinase inhibitor PTK/ZK enhances the anti-tumor effects of interferon-α/5- fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol 2011; 18: 589-596.